Detalles de la búsqueda
1.
Clinical outcomes of NSCLC patients experiencing early immune-related adverse events to PD-1/PD-L1 checkpoint inhibitors leading to treatment discontinuation.
Cancer Immunol Immunother
; 71(4): 865-874, 2022 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-34462870
2.
Serum levels of VCAM-1 are associated with survival in patients treated with nivolumab for NSCLC.
Eur J Clin Invest
; 52(1): e13668, 2022 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-34390488
3.
Triage process for the assessment of coronavirus disease 2019-positive patients with cancer: The ONCOVID prospective study.
Cancer
; 127(7): 1091-1101, 2021 04 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-33270908
4.
Trastuzumab Deruxtecan: Changing the Destiny of HER2 Expressing Solid Tumors.
Int J Mol Sci
; 22(9)2021 Apr 30.
Artículo
en Inglés
| MEDLINE | ID: mdl-33946310
5.
Impact of BMI on Survival Outcomes of Immunotherapy in Solid Tumors: A Systematic Review.
Int J Mol Sci
; 22(5)2021 Mar 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-33807855
6.
Clinicopathologic correlates of first-line pembrolizumab effectiveness in patients with advanced NSCLC and a PD-L1 expression of ≥ 50.
Cancer Immunol Immunother
; 69(11): 2209-2221, 2020 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-32474768
7.
Serum PCSK9 levels at the second nivolumab cycle predict overall survival in elderly patients with NSCLC: a pilot study.
Cancer Immunol Immunother
; 68(8): 1351-1358, 2019 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-31327024
8.
Targeting Immune-Related Biological Processes in Solid Tumors: We do Need Biomarkers.
Int J Mol Sci
; 20(21)2019 Nov 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-31683784
9.
Serial Troponin for Early Detection of Nivolumab Cardiotoxicity in Advanced Non-Small Cell Lung Cancer Patients.
Oncologist
; 23(8): 936-942, 2018 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-29567824
10.
Circulating Cell-Free DNA and Circulating Tumor Cells as Prognostic and Predictive Biomarkers in Advanced Non-Small Cell Lung Cancer Patients Treated with First-Line Chemotherapy.
Int J Mol Sci
; 18(5)2017 May 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-28492516
11.
Hematopoietic growth factors in lung cancer.
Curr Opin Oncol
; 28(2): 135-44, 2016 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-26742020
12.
Performance comparison of two commercial human whole-exome capture systems on formalin-fixed paraffin-embedded lung adenocarcinoma samples.
BMC Cancer
; 16: 692, 2016 08 30.
Artículo
en Inglés
| MEDLINE | ID: mdl-27578032
13.
Next-Generation Sequencing Workflow for NSCLC Critical Samples Using a Targeted Sequencing Approach by Ion Torrent PGM™ Platform.
Int J Mol Sci
; 16(12): 28765-82, 2015 Dec 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-26633390
14.
Role of immunotherapy in the treatment of advanced non-small-cell lung cancer.
Future Oncol
; 10(1): 79-90, 2014 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-24328411
15.
Management of patients with extensive small-cell lung cancer in the immunotherapy era: an Italian consensus through a Delphi approach.
Crit Rev Oncol Hematol
; : 104247, 2024 Jan 31.
Artículo
en Inglés
| MEDLINE | ID: mdl-38307393
16.
Glyceraldehyde-3-phosphate dehydrogenase gene over expression correlates with poor prognosis in non small cell lung cancer patients.
Mol Cancer
; 12(1): 97, 2013 Aug 29.
Artículo
en Inglés
| MEDLINE | ID: mdl-23988223
17.
Prognostic Role of Soluble and Extracellular Vesicle-Associated PD-L1, B7-H3 and B7-H4 in Non-Small Cell Lung Cancer Patients Treated with Immune Checkpoint Inhibitors.
Cells
; 12(6)2023 03 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-36980174
18.
First-line nivolumab plus ipilimumab for metastatic non-small cell lung cancer, including patients with ECOG performance status 2 and other special populations: CheckMate 817.
J Immunother Cancer
; 11(2)2023 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-36725084
19.
Safety of extended interval dosing immune checkpoint inhibitors: a multicenter cohort study.
J Natl Cancer Inst
; 115(7): 796-804, 2023 07 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-37042716
20.
Evaluation of CTLA-4 expression and relevance as a novel prognostic factor in patients with non-small cell lung cancer.
Cancer Immunol Immunother
; 61(9): 1463-72, 2012 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-22318401